USFDA refuses admission to APIs manufactured by Ipca Laboratories

At its API manufacturing facility at Ratlam (Madhya Pradesh)

Ipca Laboratories has received a communication from USFDA stating that all the drugs manufactured at the Company's API manufacturing facility at Ratlam (Madhya Pradesh) will be henceforth refused admission into United States (except API Chloroquine Phosphate, which will be reconsidered if shortage and/or medical necessity implication change) until the Company can demonstrate that the drugs manufactured at this manufacturing site and intended for the US market are in compliance with cGMP.

Powered by Capital Market - Live News